Sun Pharmaceutical Industries rises on launching SEZABY in U.S.
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Sun Pharmaceutical Industries is currently trading at Rs. 1044.00, up by 4.05 points or 0.39% from its previous closing of Rs. 1039.95 on the BSE.
The scrip opened at Rs. 1040.10 and has touched a high and low of Rs. 1050.10 and Rs. 1034.15 respectively. So far 9079 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1070.80 on 02-Nov-2022 and a 52 week low of Rs. 789.75 on 17-Jun-2022.
Last one week high and low of the scrip stood at Rs. 1054.75 and Rs. 1017.00 respectively. The current market cap of the company is Rs. 250010.70 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.01% and 9.51% respectively.
Sun Pharmaceutical Industries and includes its subsidiaries have launched SEZABY (phenobarbital sodium) in the U.S. for the treatment of neonatal seizures. SEZABY is the first and only product approved by the U.S. Food and Drug Administration (USFDA) for the treatment of neonatal seizures in term and preterm infants. SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection. It was granted orphan drug designation by the USFDA for the treatment of neonatal seizures.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
